Physician

Sameh Mikhail, M.D.

According to 2025 Medicare claims, Sameh Mikhail, M.D. (NPI: 1447455720) practices hematology/oncology in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 43219-1530.

Mikhail's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 275 traditional Medicare patients, billed 83,301 HCPCS/CPT codes, and received $1,846,348 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 748 prescription claims across 176 beneficiaries totaling $2,217,102 in drug costs, led by Revlimid (Lenalidomide). DME data shows 154 claims. Open Payments data shows 116 records totaling $198,329. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $64,312 to $1,846,348. Similarly, Part D prescription costs have moved sharply higher in recent years, from $255,483 to $2,217,102. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $19,635 to $1,419.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	244	785	$64,312
2016	289	4,037	$83,287
2017	313	47,756	$551,041
2018	315	80,814	$1,060,687
2019	366	94,388	$1,130,980
2020	267	72,421	$754,856
2021	256	87,419	$1,200,069
2022	331	82,040	$1,508,859
2023	283	92,910	$1,638,799
2024	275	83,301	$1,846,348

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	72	252	$255,483
2016	58	158	$205,445
2017	94	502	$390,414
2018	127	605	$464,950
2019	154	685	$721,736
2020	148	818	$1,443,455
2021	174	802	$1,164,859
2022	181	805	$2,127,562
2023	192	867	$1,389,661
2024	176	748	$2,217,102

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	71	355	$84,837
2016	69	193	$52,244
2017	N/R	117	$25,960
2018	N/R	71	$11,415
2019	N/R	24	$2,643
2020	N/R	88	$7,842
2021	42	227	$13,468
2022	27	153	$4,849
2023	N/R	175	$28,625
2024	22	154	$4,277

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	135	428	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	84	102	$60
36415	Insertion of needle into vein for collection of blood sample	186	624	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	186	804	$8
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	69	11,551	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	37	1,036	$561,366
Tagrisso	Osimertinib Mesylate	18	540	$284,794
Brukinsa	Zanubrutinib	15	450	$170,622
Somatuline Depot	Lanreotide Acetate	14	392	$125,757
Lenalidomide	Lenalidomide	13	280	$116,025

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	11	46	$1,795
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	49	$922
J8700	Temozolomide, oral, 5 mg	N	N/R	18	$846
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	25	$539
J8520	Capecitabine, oral, 150 mg	N	N/R	16	$175

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	105	$18,056	EMD Serono, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	11	$180,272	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sameh Mikhail, M.D.?

Tedicare shows public-source Medicare data for Sameh Mikhail, M.D. (NPI 1447455720), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sameh Mikhail, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Sameh Mikhail, M.D.?

Sameh Mikhail, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Sameh Mikhail, M.D. have Open Payments data?

Sameh Mikhail, M.D. has 116 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.